Kezar Life Sciences, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
18.75
|
|
Average Rating
|
4.75
|
|
# Strong Buys
|
3
|
|
# Buys
|
1
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.27
|
-0.25
|
0.02
|
7.41%
|
|
2022-06-30
|
-0.28
|
-0.25
|
0.03
|
10.71%
|
|
2022-03-31
|
-0.28
|
-0.26
|
0.02
|
7.14%
|
|
2021-12-31
|
-0.30
|
-0.25
|
0.05
|
16.67%
|
|
2021-09-30
|
-0.26
|
-0.28
|
-0.02
|
-7.69%
|
|
2021-06-30
|
-0.26
|
-0.25
|
0.01
|
3.85%
|
|
2021-03-31
|
-0.24
|
-0.25
|
-0.01
|
-4.17%
|
|
2020-12-31
|
-0.23
|
-0.22
|
0.01
|
4.35%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-0.76
|
|
2021-12-31
|
-1.03
|
|
2020-12-31
|
-0.97
|
|
2019-12-31
|
-1.84
|
|
2018-12-31
|
-8.58
|
|
2017-12-31
|
0.02
|